DJIA 18,096.90 -106.47 -0.58%
NASDAQ 4,967.14 -12.76 -0.26%
S&P 500 2,098.53 -9.25 -0.44%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

company name or ticker

Insider Trading Alert - SRPT, SNA And TUP Traded By Insiders

Sarepta Therapeutics Inc.'s Price Target Was Slashed By 27% -- Time to Panic?

It's been a rough 12 months for Sarepta Therapeutics, and it got even rougher on Monday following a substantial price target cut from a Wall Street firm. Find out whether this price cut is justified and what investors should consider doing next.

Did Researchers Just Discover a Functional Cure for Duchenne Muscular Dystrophy?

Duchenne muscular dystrophy has no cure, and it often kills its victims by their mid-20s. However, a new international study lends hope that a functional cure to this disease could be in the offing.

Sarepta Therapeutics (SRPT) Q4 2014 Results - Earnings Call Webcast

Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog

Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog

Will Exelixis (EXEL) Miss Estimates this Earnings Season? - Analyst Blog

Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks - Earnings ESP

Why One Analyst Sees Over 50% Upside in Sarepta

Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval

See More Articles...